Plain-English translation of NCT06830018 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medication called nano-crystalline megestrol acetate to see if it can help reduce the severe fatigue and loss of appetite that often comes with advanced stomach or colon cancer. Half of participants will receive the medication combined with their standard cancer treatment, while the other half will receive standard treatment alone. The study wants to find out if adding this medication helps people feel less exhausted and improves their quality of life.
Cancer-related fatigue is one of the most common and distressing side effects of advanced gastric and colorectal cancer, and it often comes with loss of appetite. There are few proven treatments specifically for this problem, so researchers want to see if this medication can help address these symptoms and improve how patients feel during their cancer care.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to either receive the new medication plus your standard cancer treatment, or standard treatment alone. You will take the medication by mouth as an oral suspension. Throughout the study, your doctors will monitor how you are feeling, measure your fatigue levels, check your appetite, and watch for any side effects. The study involves about 76 participants across multiple hospitals, and your participation will help doctors understand if this treatment can help other patients with cancer-related fatigue in the future.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China